An eight week comparison of the investigational drug GW590735, placebo, and the marketed drug fenofibrate intended to increase the levels of "good cholesterol" and decrease levels of "bad cholesterol" in healthy patients with low levels of good cholesterol and high levels of bad cholesterol.

A multi-center, three-staged, randomized, parallel group, sequential, double-blind, fenofibrate-and placebo-controlled dose-response evaluation of the safety, tolerability, and effects on plasma HDLc and TG of eight weeks treatment with 1µg to 20µg daily doses of GW590735 in otherwise healthy subjects with low HDLc, mildly to moderately elevated TG, and normal LDLc

Inclusion criteria:

• High-density lipoprotein cholesterol less than or equal to 45 mg/dL.
• Triglycerides greater than or equal to 120 mg/dL and less than or equal to 500 mg/dL.
• Women must be surgically sterile or postmenopausal.

Exclusion criteria:

• Heart disease
• Diabetes